Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
ALTB-268 for Ulcerative Colitis
Recruiting1 awardPhase 2
Louisville, Kentucky
This trial will assess a new drug, ALTB-268, for safety and effectiveness in treating moderate to severe ulcerative colitis. Subjects will receive weekly doses for 12 weeks, followed by bi-weekly doses for 40 weeks.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service